Bio-Techne Set to Report Q2 Results Amid Positive Trends

Bio-Techne Corporation is poised to announce its second-quarter results, with expected EPS of $0.33. Strong performance in the Diagnostics segment and bullish analyst outlook may positively affect stock prices.

Date: 20-01-2025

AI Rating: 7

Earnings Per Share (EPS)
Bio-Techne's adjusted EPS for fiscal 2025 is projected to be $1.68, reflecting a 7% increase from $1.57 in fiscal 2024. EPS expectations for future fiscal periods show a significant anticipated growth of 20.2% to $2.02 in fiscal 2026. This positive EPS trajectory indicates strong future earnings potential, which could boost investor confidence.
Revenue Growth
The report highlights a year-over-year growth in net sales of 4.5% to $289.5 million, surpassing Wall Street's expectations by 3.1%. Particularly, the Diagnostics & Spatial Biology segment drove this growth, showcasing a substantial revenue increase of 14.3% year-over-year to $83.2 million. Sustained revenue growth reinforces the company's market position and could influence stock performance positively. Overall, the positive trend in earnings and revenue growth are likely to bolster investor sentiment.
Stock Performance and Analyst Ratings
Bio-Techne's stock has recently performed well, indicated by a 7.5% increase following better-than-expected Q1 results. Additionally, the stock has a consensus “Strong Buy” rating, with a mean price target indicating a 12.1% premium to current price levels. This bullish outlook from analysts further supports the potential for price appreciation in response to the upcoming earnings announcement.
Overall, the report presents a favorable outlook for Bio-Techne, with strong EPS growth, solid revenue increase, and positive market sentiment.

Stocks: TECH